XML 107 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
Segment Information (Notes)
 12 Months Ended
Dec. 31, 2014
Segment Reporting [Abstract]  
Segment Information

The Company is organized in two operating segments, LTC and SCG. These segments are based on the operations of the underlying businesses and the customers they serve. The Company’s larger reportable segment is LTC, which primarily provides distribution of pharmaceuticals, related pharmacy consulting and other ancillary services. LTC’s customers are primarily skilled nursing, assisted living and other providers of healthcare services. The Company’s other reportable segment is SCG, which provides specialty pharmacy and key commercialization services for the biopharmaceutical industry. The primary components of the “Corporate/Other” segment are the Company’s corporate management oversight and administration, including its information technology and data management services, as well as other consolidating and eliminating entries, which have not been charged to reportable segments. The Company evaluates the performance of its segments based on revenue and operating income, and does not include segment assets or nonoperating income/expense items for management reporting purposes.

The table below presents information about the Company’s segments as of and for the years ended December 31, 2014, 2013 and 2012 (in thousands):

 
 
For the years ended December 31,
2014:
 
LTC
 
SCG
 
Corporate/Other
 
Consolidated
Totals
Net sales
 
$
4,750,121

 
$
1,667,152

 
$
342

 
$
6,417,615

Depreciation and amortization expense
 
(69,089
)
 
(4,498
)
 
(58,707
)
 
(132,294
)
Settlement, litigation and other related charges
 
(42,818
)
 
—

 
—

 
(42,818
)
Other charges, net
 
(73,248
)
 
(566
)
 
(65,439
)
 
(139,253
)
Operating income (loss) from continuing operations
 
516,086

 
136,373

 
(225,146
)
 
427,313

2013:
 
 

 
 

 
 

 
 

Net sales
 
$
4,627,871

 
$
1,384,003

 
$
1,524

 
$
6,013,398

Depreciation and amortization expense
 
(71,310
)
 
(4,539
)
 
(57,111
)
 
(132,960
)
Settlement, litigation and other related charges
 
(167,465
)
 
—

 
—

 
(167,465
)
Other charges, net
 
(45,950
)
 
—

 
(53,852
)
 
(99,802
)
Operating income (loss) from continuing operations
 
420,646

 
113,243

 
(236,035
)
 
297,854

2012:
 
 

 
 

 
 

 
 

Net sales
 
$
4,789,551

 
$
1,078,627

 
$
10,286

 
$
5,878,464

Depreciation and amortization expense
 
(69,582
)
 
(8,431
)
 
(50,524
)
 
(128,537
)
Settlement, litigation and other related charges
 
(49,175
)
 
(200
)
 
—

 
(49,375
)
Other charges, net
 
(2,568
)
 
—

 
(63,145
)
 
(65,713
)
Operating income (loss) from continuing operations
 
562,379

 
92,671

 
(244,715
)
 
410,335


The Company’s continuing operations are located in the U.S. One pharmacy located in Canada, which was not material to the consolidated sales or total assets of Omnicare, was disposed of in the third quarter of 2012.